20:30:05 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriMedicinteknik
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo.

Kalender

2023-04-17 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-19 Ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-12-29 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-30 Kvartalsrapport 2020-Q1
2019-12-20 Extra Bolagsstämma 2019
2019-06-27 Årsstämma 2019
2019-06-03 Ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50
2020-10-22 15:13:54
The Danish Medicines Agency has given its recommendation for further development
of the SoftOx inhalation solution for the treatment of respiratory infections,
including COVID-19.

The SoftOx Inhalation Project aims to develop an inhalation solution for the
treatment of respiratory infections. This has the potential to be a breakthrough
in the treatment of respiratory infections including Covid-19 infections.
Following a scientific advisory meeting with the Danish Medicines Agency, a
favorable development path has been suggested to be able to start testing in
humans as soon as possible. 

- It is now expected that the first studies in humans can start as early as the
second quarter of 2021. SoftOx will therefore immediately start preparations to
provide the necessary documentation that involves further safety studies in
animal models, says Geir Almås, CEO of SoftOx Solutions. 

- The need for new solutions treating respiratory tract infections is
significant, this is a market which with conservative estimates for the EU and
the US is approximately 12 billion USD. The number can probably be doubled
looking in a global perspective, continue Almås.

 This technology is unique, it is simple, exceptionally effective and does not
trigger resistance. The effect is also independent of possible new mutated
variants, as recently reported for the Corona virus. 

- My team and I believe that we are facing a breakthrough in the treatment of
difficult infections, both viral and bacterial. We have tested SoftOx solutions
in the respiratory tract and we see that this can be an important treatment
principle that can help fight the ongoing pandemic and future epidemics and
pandemics ", says Professor of Microbiology and trial leader Thomas Bjarnsholt
at the University of Copenhagen.

For more information contact:
Professor Thomas Bjarnsholt; tbjarnsholt@sund.ku.dk +45 206 59 888
CEO Geir Almås; geir.almaas@soft-ox.com +47 977 59 071

Professor Thomas Bjarnsholt is a member of the company's Scientific Advisory
Board and has 20.000 stock options in SoftOx Solutions.